Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 5;13:999163. doi: 10.3389/fimmu.2022.999163

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Odak, Sikora, Riemann, Bayir, Beck, Drenker, Xiao, Schneider, Dammann, Stadler, Eder, Ganser, Förster, Koenecke and Schultze-Florey

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Study work flow and response to DLI. (A) Every patient is represented by one line with color coding giving details of timing and duration of GVL (green), noGVL (orange) and relapse (red) and the timing of concomitant antineoplastic treatment (blue). Application of DLIs is shown with double lines, timing of the first (F) and last (L) samples post DLI is marked in the time line of each patient. Follow-up time was 24 months. Arrows indicate continued survival beyond the study follow up, # indicates second allogeneic hematopoietic stem cell transplantation, † indicates death. (B) The workflow is shown. After sampling, PBMCs were measured with spectral flow cytometry. Data was then manually pre-gated on T cells for cluster analysis, which were subsequently statistically evaluated. Figure 1B was created with BioRender.com.